{"gene":"ADORA2A","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":1990,"finding":"RDC8 (ADORA2A) encodes an adenosine A2 receptor that, when expressed in Y1 adrenal cells, dog thyrocytes, and Xenopus oocytes, constitutively activates adenylyl cyclase and the cAMP cascade; this activity was inhibited by adenosine deaminase and adenosine A2 receptor inhibitors. COS7 cells transfected with RDC8 cDNA acquired adenosine A2 receptor binding characteristics.","method":"Heterologous expression in multiple cell systems (Y1 adrenal cells, primary thyrocytes, Xenopus oocytes, COS7 cells); adenylyl cyclase activity assay; radioligand binding assay; pharmacological inhibition","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted receptor activity in multiple heterologous systems with pharmacological validation and binding assays; replicated across three cell systems in single study","pmids":["2125216"],"is_preprint":false},{"year":1991,"finding":"ADORA2A (RDC8) mRNA is expressed exclusively by enkephalin-containing medium spiny neurons in the rat striatum, and not by substance P-containing or cholinergic neurons, as determined by in situ hybridization histochemistry.","method":"In situ hybridization histochemistry combined with neurochemical phenotyping in rat caudate-putamen","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in situ hybridization with cell-type co-localization, single lab but two orthogonal marker systems tested","pmids":["1713612"],"is_preprint":false},{"year":1996,"finding":"The human ADORA2A gene consists of two exons interrupted by an intron of ~6.4 kb, and the gene is localized to chromosome 22q11.2 by fluorescent in situ hybridization and PCR analysis of human-hamster hybrid cell panels.","method":"Genomic cloning, sequence analysis, fluorescent in situ hybridization (FISH), PCR of human-hamster hybrid cell panels","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct chromosomal mapping with two orthogonal methods (FISH and somatic cell hybrid PCR), single lab","pmids":["8670304"],"is_preprint":false},{"year":2013,"finding":"ADORA2A diplotype AA (homozygous haplotype A) is associated with higher ADORA2A mRNA and protein expression in both brain samples and lymphoblasts, and with higher cAMP production in lymphoblasts in response to adenosine, compared to BB diplotype, demonstrating that genetic variation functionally alters ADORA2A-mediated cAMP signaling.","method":"mRNA expression quantification in brain and lymphoblasts; Western blot for protein; cAMP assay in lymphoblasts stratified by diplotype","journal":"Neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three orthogonal functional readouts (mRNA, protein, cAMP) in two tissue types, single lab","pmids":["23535492"],"is_preprint":false},{"year":2019,"finding":"Inducible endothelial cell-specific deletion of Adora2a in mice protects against blood-brain barrier (BBB) breakdown, vascular inflammation, deficits in hippocampal synaptic plasticity, and cognitive impairment induced by high-fat diet/insulin resistance, establishing that Adora2a-mediated signaling in vascular endothelial cells directly mediates BBB disruption.","method":"Inducible conditional knockout (endothelial-specific Adora2a deletion); BBB permeability assays (sodium fluorescein, Evans blue); transmission electron microscopy of tight junctions; behavioral memory tests; electrophysiology (synaptic plasticity)","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic ablation with multiple orthogonal phenotypic readouts (permeability, EM ultrastructure, cognition, LTP), plus pharmacological validation","pmids":["30886019"],"is_preprint":false},{"year":2020,"finding":"SNP rs2298383 in ADORA2A reduces ADORA2A mRNA transcript levels in peripheral blood mononuclear cells (PBMCs); the TT mutated genotype (lower ADORA2A expression) is associated with higher IFNG mRNA levels, suggesting that reduced A2AR signaling promotes a pro-inflammatory phenotype.","method":"RT-qPCR quantification of ADORA2A, IFNG, and IL4 mRNA in PBMCs stratified by rs2298383 genotype; correlation analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct mRNA quantification showing genotype-dependent expression differences with functional immune correlate, single lab, two transcriptional readouts","pmids":["32182774"],"is_preprint":false},{"year":2020,"finding":"Adenosine activates ADORA2A to promote phosphorylation of Stat3 and Akt, resulting in increased Ang (angiogenin)-dependent angiogenesis in placental endothelial cells; ADORA2A overexpression or adenosine treatment reverses impaired angiogenesis in IUGR placenta in vitro and in vivo.","method":"In vitro angiogenesis assays; Matrigel plug assay in vivo; Western blot for phospho-Stat3 and phospho-Akt; ADORA2A overexpression and pharmacological manipulation in diet-induced IUGR mouse model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo gain-of-function with defined downstream signaling (pStat3/pAkt) and functional angiogenesis readout, single lab","pmids":["37051927"],"is_preprint":false},{"year":2023,"finding":"ADORA2A activation rewires proline metabolism via an ERK/MYC/PYCR cascade; increased proline synthesis promotes SIRT6/7-mediated deacetylation of H3K27, driving a neuroendocrine transcriptional program. Genetic ablation of Adora2a in mouse models inhibits neuroendocrine prostate and lung cancer development and prevents adenocarcinoma-to-neuroendocrine phenotypic transition.","method":"Genetically engineered mouse models (Adora2a ablation); RNA-seq; ChIP for H3K27ac/H3K27me3; metabolomics (proline); Western blot for ERK/MYC/PYCR/SIRT6/7; pharmacological ADORA2A blockade in vivo; in vitro signaling assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (metabolomics, epigenomics, transcriptomics, genetic KO, pharmacology) in both mouse models and cell lines defining a complete mechanistic pathway","pmids":["38099497"],"is_preprint":false},{"year":2022,"finding":"JMJD3-mediated H3K27me3 demethylation upregulates ADORA2A expression in macrophages (with C/EBPβ as an additional transcriptional enhancer of ADORA2A), and elevated ADORA2A inhibits caspase-3 cleavage to suppress macrophage apoptosis during LPS-induced acute lung injury.","method":"Chromatin immunoprecipitation (ChIP) for H3K27me3 at ADORA2A locus; JMJD3 inhibition/overexpression; ADORA2A knockdown; flow cytometry for apoptosis; TUNEL staining; Western blot for cleaved caspase-3; in vivo ALI mouse model","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates epigenetic regulation of ADORA2A, knockdown with apoptosis readout, in vitro and in vivo, single lab","pmids":["36456564"],"is_preprint":false},{"year":2020,"finding":"ADORA2A is upregulated by ADORA2A methylation via miR-497/miR-195 downregulation in ossification of the posterior longitudinal ligament (OPLL); miR-195 and miR-497 directly target ADORA2A 3'UTR, and overexpression of these miRNAs inactivates the cAMP/PKA signaling pathway via ADORA2A downregulation to reduce osteogenic differentiation of PLL cells.","method":"Luciferase reporter assay (miRNA target validation); qRT-PCR and Western blot for ADORA2A, osteogenic markers; cAMP/PKA pathway analysis; bisulfite sequencing for promoter methylation; demethylation with 5-aza-2'-deoxycytidine","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — validated miRNA-ADORA2A interaction and downstream cAMP/PKA signaling with multiple methods, single lab","pmids":["32432317"],"is_preprint":false},{"year":2023,"finding":"ADORA2A knockdown in colorectal carcinoma cell lines (SW620, HCT116) inhibits cell proliferation, migration, and invasion, reduces anti-apoptotic Bcl-2 expression, and increases Bax/cleaved caspase-3/cleaved caspase-9, while ADORA2A overexpression has the opposite effect; these effects are mediated through the PI3K/AKT signaling pathway.","method":"siRNA knockdown; plasmid overexpression; CCK-8, colony formation, wound healing, transwell assays; flow cytometry for apoptosis; Western blot for PI3K/AKT pathway proteins and apoptosis markers","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function with multiple cellular readouts and defined pathway involvement, single lab","pmids":["37945707"],"is_preprint":false},{"year":2025,"finding":"PARP1-mediated PARylation of POLG leads to PARylation-dependent ubiquitination and downregulation of POLG, causing mitochondrial dysfunction and subsequent activation of Adora2a/Rap1 signaling, which drives vascular smooth muscle cell ferroptosis and vascular calcification.","method":"VSMC β-glycerophosphate calcification model; PARP1 knockdown (Parp1flox/flox Tagln-Cre+ mice); AAV9-sh-POLG injection; RNA-sequencing; Western blot for PARylation, ubiquitination, Adora2a, Rap1; mitochondrial function assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic in vivo model with RNA-seq pathway identification and Western blot validation, single lab, downstream signaling defined","pmids":["40401372"],"is_preprint":false},{"year":2025,"finding":"AMP is converted to adenosine by ecto-5'-nucleotidase (CD73), and the resulting adenosine activates ADORA2A signaling to reduce DNA methylation of hormone-sensitive lipase (HSL) promoter, promoting HSL transcription and white fat lipolysis. This effect is partially eliminated in ADORA2A knockout mice and restored by ADORA2A re-expression.","method":"ADORA2A knockout mice; ADORA2A re-expression; bisulfite sequencing for HSL methylation; qRT-PCR for HSL transcription; CD73 inhibition; metabolic phenotyping on high-fat diet","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with rescue and defined epigenetic mechanism (HSL methylation), multiple methods, single lab","pmids":["39976204"],"is_preprint":false},{"year":2022,"finding":"ADORA2A and DRD2 form heterodimers that co-localize in human retinal pigment epithelial (RPE) cells, as demonstrated by immunofluorescence and co-immunoprecipitation. Treatment with the ADORA2A antagonist 7-methylxanthine reduces ADORA2A expression and increases DRD2, ERK1/2, and phospho-ERK1/2 expression, indicating that ADORA2A inhibits the DRD2/ERK signaling pathway in these cells.","method":"Co-immunoprecipitation; immunofluorescence co-localization; siRNA knockdown of ADORA2A or DRD2; Western blot for ERK1/2, pERK1/2, DRD2; pharmacological treatment with 7-MX","journal":"Ophthalmic research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and co-localization with functional downstream signaling validation, single lab","pmids":["35724635"],"is_preprint":false},{"year":2024,"finding":"Retina-specific AdoRA2a knockout (AdoRA2a-CKO) mice and pharmacological AdoRA2a antagonism with KW6002 both attenuate form-deprivation myopia progression in mice. AdoRA2a co-localizes with dopamine D2 receptor (Drd2) in the retina, and KW6002 has no inhibitory effect on myopia in Drd2-CKO mice, establishing that retinal AdoRA2a acts upstream of Drd2 to regulate myopia.","method":"Retina-specific conditional knockout (AdoRA2a-CKO); Drd2-CKO epistasis experiment; pharmacological antagonism (KW6002); refraction measurement; immunofluorescence co-localization; measurement of retinal adenosine and CD39/CD73","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double KO experiment) with conditional KO and pharmacological confirmation, multiple orthogonal approaches defining AdoRA2a-Drd2 pathway","pmids":["41533917"],"is_preprint":false},{"year":2024,"finding":"Brain-specific RagA overexpression in transgenic mice upregulates ADORA2A expression in prefrontal cortex (confirmed by Western blot and RNA-seq), and the ADORA2A inhibitor istradefylline attenuates depressive-like behaviors in these mice, placing ADORA2A downstream of the RagA-p70S6K signaling pathway in depression-related behavior.","method":"RagA transgenic mice; RNA-seq of prefrontal cortex; Western blot for ADORA2A and phospho-p70S6K; behavioral assessments (depression-like tests); pharmacological ADORA2A inhibition with istradefylline; metabolomics","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic overexpression with RNA-seq identification and pharmacological rescue, single lab, defined pathway position","pmids":["39373701"],"is_preprint":false},{"year":2024,"finding":"Using a MiniPromoter derived from ADORA2A regulatory regions (Ple389), selective expression was achieved in medium spiny neurons of the striatum in mice and non-human primates, with high co-localization with dopamine D2 receptor-expressing MSNs and DARPP32, directly establishing that ADORA2A regulatory elements drive expression in D2-MSNs.","method":"rAAV-PHP.B delivery of MiniPromoter-reporter constructs; intravenous and intracerebroventricular injection in mice and NHP; immunofluorescence co-localization with D2R and DARPP32; histological analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo localization experiments in two species with orthogonal marker co-localization, single lab","pmids":["39548191"],"is_preprint":false},{"year":2023,"finding":"Genistein activates ADORA2A in renal tubular cells (NRK-52E); ADORA2A overexpression mimics genistein's protective effects against hypoxia/reoxygenation-induced oxidative stress and apoptosis, while ADORA2A knockdown partially abrogates genistein's protection, establishing ADORA2A as the functional mediator of genistein's renoprotective effects.","method":"ADORA2A overexpression and siRNA knockdown in NRK-52E cells; H/R injury model; in vivo renal IR mouse model; cell proliferation, apoptosis, and oxidative stress assays","journal":"Human & experimental toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with in vitro and in vivo correlation, single lab","pmids":["36932924"],"is_preprint":false}],"current_model":"ADORA2A encodes a G protein-coupled adenosine A2A receptor that constitutively activates adenylyl cyclase/cAMP signaling upon adenosine binding; it is selectively expressed in striatal D2-type medium spiny neurons (enkephalinergic subpopulation), and in endothelial, immune, and other cell types where it mediates diverse downstream cascades including ERK/MYC/PYCR-driven proline synthesis and H3K27 deacetylation (promoting neuroendocrine lineage plasticity), PI3K/AKT (promoting cancer cell survival), Stat3/Akt (promoting angiogenesis), cAMP/PKA (regulating osteogenesis), and Adora2a/Rap1 (promoting VSMC ferroptosis), as well as heterodimerizing with DRD2 to modulate ERK signaling; in the brain its signaling mediates caffeine-sensitive sleep regulation, vigilance, and BBB integrity, and its expression is itself regulated epigenetically by H3K27me3 demethylation (via JMJD3) and by miR-195/miR-497-dependent promoter methylation."},"narrative":{"mechanistic_narrative":"ADORA2A encodes a G protein-coupled adenosine A2A receptor that, upon adenosine binding, activates adenylyl cyclase and the cAMP cascade — an activity reconstituted in multiple heterologous expression systems and blocked by adenosine deaminase and A2 receptor antagonists [PMID:2125216]. In the brain it is expressed selectively by enkephalin-containing, D2-type medium spiny neurons of the striatum, and its regulatory elements are sufficient to drive D2-MSN-specific expression in mice and non-human primates [PMID:1713612, PMID:39548191]. Through cAMP/PKA the receptor signals in diverse peripheral tissues: it drives osteogenic differentiation [PMID:32432317], promotes white adipose lipolysis by reducing methylation of the HSL promoter [PMID:39976204], and supports endothelial functions including Stat3/Akt-dependent angiogenesis [PMID:37051927] and, when active in vascular endothelium, blood-brain barrier breakdown and associated cognitive impairment [PMID:30886019]. In cancer contexts ADORA2A promotes survival and progression: it sustains colorectal carcinoma proliferation and invasion via PI3K/AKT [PMID:37945707], and rewires proline metabolism through an ERK/MYC/PYCR cascade that fuels SIRT6/7-mediated H3K27 deacetylation to drive a neuroendocrine transcriptional program in prostate and lung cancer [PMID:38099497]. The receptor also forms heterodimers with the dopamine D2 receptor (DRD2), acting upstream of DRD2/ERK signaling in retinal cells to modulate processes including myopia progression [PMID:35724635, PMID:41533917]. ADORA2A expression is itself epigenetically controlled — induced by JMJD3-mediated H3K27me3 demethylation in macrophages [PMID:36456564] and repressed by miR-195/miR-497 and promoter methylation [PMID:32432317] — and common diplotype variation functionally tunes its mRNA, protein, and cAMP output [PMID:23535492].","teleology":[{"year":1990,"claim":"Established that the orphan clone RDC8 encodes a functional adenosine A2 receptor coupled to cAMP, defining the receptor's core biochemical activity.","evidence":"Heterologous expression in Y1 adrenal cells, thyrocytes, Xenopus oocytes and COS7 cells with adenylyl cyclase and radioligand binding assays plus pharmacological inhibition","pmids":["2125216"],"confidence":"High","gaps":["No structural basis for adenosine binding or G protein coupling defined","Did not address endogenous tissue distribution or physiological role"]},{"year":1991,"claim":"Localized receptor expression to a defined neuronal population, linking ADORA2A to striatal circuitry by showing it marks enkephalinergic medium spiny neurons.","evidence":"In situ hybridization with neurochemical phenotyping in rat caudate-putamen","pmids":["1713612"],"confidence":"Medium","gaps":["Descriptive expression mapping without functional consequence","Rodent striatum only"]},{"year":1996,"claim":"Resolved the human gene architecture and chromosomal position, providing the genomic substrate for later variant and regulatory studies.","evidence":"Genomic cloning, FISH, and PCR of human-hamster hybrid panels","pmids":["8670304"],"confidence":"Medium","gaps":["No regulatory element or promoter function assigned","No link to phenotype"]},{"year":2013,"claim":"Demonstrated that common ADORA2A haplotype variation functionally alters signaling output, connecting genotype to expression and cAMP response.","evidence":"Diplotype-stratified mRNA, Western blot, and cAMP assays in human brain and lymphoblasts","pmids":["23535492"],"confidence":"Medium","gaps":["Correlative across genotype groups, no causal allelic substitution","Single lab"]},{"year":2019,"claim":"Showed that endothelial ADORA2A signaling causally drives blood-brain barrier breakdown and cognitive impairment, defining a vascular role distinct from its neuronal one.","evidence":"Endothelial-specific inducible Adora2a knockout with BBB permeability, EM, behavior and LTP readouts plus pharmacology","pmids":["30886019"],"confidence":"High","gaps":["Downstream effector pathway in endothelium not resolved","Mouse model only"]},{"year":2020,"claim":"Connected ADORA2A to angiogenesis and immune tone, identifying Stat3/Akt-dependent angiogenesis and a genotype-linked pro-inflammatory phenotype with reduced receptor expression.","evidence":"Placental endothelial angiogenesis and Matrigel assays with pStat3/pAkt readouts (37051927); rs2298383-stratified PBMC RT-qPCR of ADORA2A/IFNG (32182774)","pmids":["37051927","32182774"],"confidence":"Medium","gaps":["Immune correlation is associative, no mechanistic link to IFNG transcription","Two distinct tissue contexts not integrated"]},{"year":2020,"claim":"Established ADORA2A as a node controlled by miRNA and promoter methylation that drives osteogenic differentiation through cAMP/PKA.","evidence":"Luciferase 3'UTR target validation, bisulfite sequencing, demethylation, and cAMP/PKA analysis in OPLL PLL cells","pmids":["32432317"],"confidence":"Medium","gaps":["Disease specificity to OPLL not generalized","Single lab"]},{"year":2022,"claim":"Defined epigenetic and dimerization-based control of the receptor: JMJD3/H3K27me3 induces ADORA2A to suppress macrophage apoptosis, and ADORA2A heterodimerizes with DRD2 to inhibit DRD2/ERK signaling.","evidence":"ChIP at ADORA2A locus with apoptosis assays in ALI model (36456564); co-IP, co-localization and ERK readouts in RPE cells (35724635)","pmids":["36456564","35724635"],"confidence":"Medium","gaps":["Anti-apoptotic mechanism downstream of receptor not detailed","Heterodimer interface and stoichiometry undefined"]},{"year":2023,"claim":"Revealed two pro-survival/pro-progression cancer axes: an ERK/MYC/PYCR-proline-SIRT6/7-H3K27 deacetylation cascade driving neuroendocrine plasticity, and PI3K/AKT-driven proliferation in colorectal carcinoma.","evidence":"GEMM Adora2a ablation with metabolomics, ChIP, RNA-seq and pharmacology (38099497); reciprocal knockdown/overexpression with PI3K/AKT and apoptosis readouts in colorectal lines (37945707)","pmids":["38099497","37945707"],"confidence":"High","gaps":["How adenosine signaling selectively engages ERK/MYC vs PI3K/AKT in different tumors unclear","Renoprotective genistein-ADORA2A axis (36932924) characterized only correlatively"]},{"year":2024,"claim":"Used genetic epistasis to place retinal ADORA2A upstream of DRD2 in controlling myopia, and positioned ADORA2A downstream of RagA-p70S6K signaling in depression-related behavior.","evidence":"Retina-specific and Drd2 double-KO epistasis with KW6002 pharmacology (41533917); RagA transgenic mice with RNA-seq and istradefylline rescue (39373701); MiniPromoter D2-MSN expression mapping (39548191)","pmids":["41533917","39373701","39548191"],"confidence":"High","gaps":["Molecular basis of ADORA2A-DRD2 functional epistasis in retina not resolved","Connection between RagA pathway and ADORA2A transcription not mechanistically defined"]},{"year":2025,"claim":"Extended ADORA2A signaling to metabolic and vascular pathology, linking CD73-derived adenosine to HSL-driven lipolysis and PARP1/POLG-driven mitochondrial dysfunction to Adora2a/Rap1-mediated VSMC ferroptosis.","evidence":"ADORA2A KO with rescue and HSL bisulfite sequencing in adipose (39976204); VSMC calcification model with PARP1/POLG genetic manipulation and RNA-seq (40401372)","pmids":["39976204","40401372"],"confidence":"Medium","gaps":["Mechanism by which receptor signaling alters HSL promoter methylation not defined","Adora2a/Rap1-ferroptosis link is correlative within the calcification model"]},{"year":null,"claim":"How a single cAMP-coupled receptor selects among its many downstream effector outcomes (cAMP/PKA, Stat3/Akt, PI3K/AKT, ERK/MYC, Rap1) across cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking ligand/cell context to effector choice","No structural data on G protein coupling or DRD2 heterodimer in the corpus","Most downstream cascades shown in single cell systems"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,6,10]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[1,16]}],"complexes":[],"partners":["DRD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29274","full_name":"Adenosine receptor A2a","aliases":[],"length_aa":412,"mass_kda":44.7,"function":"Receptor for adenosine (By similarity). The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P29274/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADORA2A","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADORA2A","total_profiled":1310},"omim":[{"mim_id":"621003","title":"TRANSCRIPTION FACTOR Sp9; SP9","url":"https://www.omim.org/entry/621003"},{"mim_id":"615073","title":"DYSTONIA 25; DYT25","url":"https://www.omim.org/entry/615073"},{"mim_id":"600446","title":"ADENOSINE A2B RECEPTOR; ADORA2B","url":"https://www.omim.org/entry/600446"},{"mim_id":"600445","title":"ADENOSINE A3 RECEPTOR; ADORA3","url":"https://www.omim.org/entry/600445"},{"mim_id":"600042","title":"MELANOCORTIN 5 RECEPTOR; MC5R","url":"https://www.omim.org/entry/600042"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":38.3},{"tissue":"brain","ntpm":108.6},{"tissue":"lymphoid tissue","ntpm":50.4}],"url":"https://www.proteinatlas.org/search/ADORA2A"},"hgnc":{"alias_symbol":["RDC8"],"prev_symbol":["ADORA2"]},"alphafold":{"accession":"P29274","domains":[{"cath_id":"1.20.1070.10","chopping":"1-312","consensus_level":"medium","plddt":93.2295,"start":1,"end":312}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29274","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29274-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29274-F1-predicted_aligned_error_v6.png","plddt_mean":80.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADORA2A","jax_strain_url":"https://www.jax.org/strain/search?query=ADORA2A"},"sequence":{"accession":"P29274","fasta_url":"https://rest.uniprot.org/uniprotkb/P29274.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29274/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29274"}},"corpus_meta":[{"pmid":"1713612","id":"PMC_1713612","title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study.","date":"1991","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1713612","citation_count":466,"is_preprint":false},{"pmid":"2125216","id":"PMC_2125216","title":"RDC8 codes for an adenosine A2 receptor with physiological constitutive activity.","date":"1990","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2125216","citation_count":259,"is_preprint":false},{"pmid":"17329997","id":"PMC_17329997","title":"A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep.","date":"2007","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17329997","citation_count":183,"is_preprint":false},{"pmid":"20520601","id":"PMC_20520601","title":"Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption.","date":"2010","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20520601","citation_count":141,"is_preprint":false},{"pmid":"21281405","id":"PMC_21281405","title":"Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.","date":"2011","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21281405","citation_count":87,"is_preprint":false},{"pmid":"30886019","id":"PMC_30886019","title":"Endothelial Adora2a Activation Promotes Blood-Brain Barrier Breakdown and Cognitive Impairment in Mice with Diet-Induced Insulin Resistance.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30886019","citation_count":81,"is_preprint":false},{"pmid":"21950736","id":"PMC_21950736","title":"Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21950736","citation_count":76,"is_preprint":false},{"pmid":"28941407","id":"PMC_28941407","title":"Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28941407","citation_count":63,"is_preprint":false},{"pmid":"23535492","id":"PMC_23535492","title":"ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23535492","citation_count":61,"is_preprint":false},{"pmid":"19565319","id":"PMC_19565319","title":"Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder.","date":"2009","source":"European child & adolescent psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19565319","citation_count":59,"is_preprint":false},{"pmid":"19591938","id":"PMC_19591938","title":"A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.","date":"2009","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/19591938","citation_count":57,"is_preprint":false},{"pmid":"22012471","id":"PMC_22012471","title":"ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex.","date":"2011","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22012471","citation_count":45,"is_preprint":false},{"pmid":"32823594","id":"PMC_32823594","title":"Effects of CYP1A2 and ADORA2A Genotypes on the Ergogenic Response to Caffeine in Professional Handball Players.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32823594","citation_count":43,"is_preprint":false},{"pmid":"31817803","id":"PMC_31817803","title":"The Impact of Genetic Variations in ADORA2A in the Association between Caffeine Consumption and Sleep.","date":"2019","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/31817803","citation_count":41,"is_preprint":false},{"pmid":"30511252","id":"PMC_30511252","title":"Impact of genetic variations in ADORA2A gene on depression and symptoms: a cross-sectional population-based study.","date":"2018","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30511252","citation_count":40,"is_preprint":false},{"pmid":"20512606","id":"PMC_20512606","title":"Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1.","date":"2010","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20512606","citation_count":38,"is_preprint":false},{"pmid":"28135712","id":"PMC_28135712","title":"Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2.","date":"2016","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/28135712","citation_count":37,"is_preprint":false},{"pmid":"8670304","id":"PMC_8670304","title":"Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8670304","citation_count":32,"is_preprint":false},{"pmid":"38099497","id":"PMC_38099497","title":"ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38099497","citation_count":30,"is_preprint":false},{"pmid":"22940476","id":"PMC_22940476","title":"Effects of ADORA2A gene variation and caffeine on prepulse inhibition: a multi-level risk model of anxiety.","date":"2012","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22940476","citation_count":28,"is_preprint":false},{"pmid":"27399166","id":"PMC_27399166","title":"Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.","date":"2016","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27399166","citation_count":28,"is_preprint":false},{"pmid":"31324842","id":"PMC_31324842","title":"Genetic Polymorphisms in ADORA2A and CYP1A2 Influence Caffeine's Effect on Postprandial Glycaemia.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31324842","citation_count":27,"is_preprint":false},{"pmid":"25872644","id":"PMC_25872644","title":"Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?","date":"2015","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/25872644","citation_count":26,"is_preprint":false},{"pmid":"30946941","id":"PMC_30946941","title":"Synergistic effects between ADORA2A and DRD2 genes on anxiety disorders in children with ADHD.","date":"2019","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/30946941","citation_count":25,"is_preprint":false},{"pmid":"34733789","id":"PMC_34733789","title":"ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34733789","citation_count":22,"is_preprint":false},{"pmid":"33235193","id":"PMC_33235193","title":"ADORA2A variation and adenosine A1 receptor availability in the human brain with a focus on anxiety-related brain regions: modulation by ADORA1 variation.","date":"2020","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33235193","citation_count":19,"is_preprint":false},{"pmid":"25629231","id":"PMC_25629231","title":"The association of ADORA2A and ADORA2B polymorphisms with the risk and severity of chronic heart failure: a case-control study of a northern Chinese population.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25629231","citation_count":19,"is_preprint":false},{"pmid":"33373678","id":"PMC_33373678","title":"Coffee effectively attenuates impaired attention in ADORA2A C/C-allele carriers during chronic sleep restriction.","date":"2020","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33373678","citation_count":18,"is_preprint":false},{"pmid":"27038930","id":"PMC_27038930","title":"Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy.","date":"2016","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/27038930","citation_count":17,"is_preprint":false},{"pmid":"22240468","id":"PMC_22240468","title":"Differential effects of ADORA2A gene variations in pre-attentive visual sensory memory subprocesses.","date":"2012","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22240468","citation_count":17,"is_preprint":false},{"pmid":"27262510","id":"PMC_27262510","title":"ADORA2A genotype modulates interoceptive and exteroceptive processing in a fronto-insular network.","date":"2016","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27262510","citation_count":16,"is_preprint":false},{"pmid":"37051927","id":"PMC_37051927","title":"Adenosine-ADORA2A Promotes Ang-Induced Angiogenesis in Intrauterine Growth Restriction Placenta via the Stat3/Akt Pathway.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37051927","citation_count":15,"is_preprint":false},{"pmid":"33262686","id":"PMC_33262686","title":"Genetic Polymorphism of ADORA2A Is Associated With the Risk of Epilepsy and Predisposition to Neurologic Comorbidity in Chinese Southern Children.","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33262686","citation_count":15,"is_preprint":false},{"pmid":"37945707","id":"PMC_37945707","title":"ADORA2A promotes proliferation and inhibits apoptosis through PI3K/AKT pathway activation in colorectal carcinoma.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37945707","citation_count":14,"is_preprint":false},{"pmid":"31695381","id":"PMC_31695381","title":"Association between ADORA2A gene polymorphisms and schizophrenia in the North Chinese Han population.","date":"2019","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/31695381","citation_count":14,"is_preprint":false},{"pmid":"26066465","id":"PMC_26066465","title":"Categorical complexities of Plasmodium falciparum malaria in individuals is associated with genetic variations in ADORA2A and GRK5 genes.","date":"2015","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26066465","citation_count":14,"is_preprint":false},{"pmid":"40401372","id":"PMC_40401372","title":"PARylation of POLG Mediated by PARP1 Accelerates Ferroptosis-Induced Vascular Calcification via Activating Adora2a/Rap1 Signaling.","date":"2025","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/40401372","citation_count":13,"is_preprint":false},{"pmid":"36456564","id":"PMC_36456564","title":"H3K27 tri-demethylase JMJD3 inhibits macrophage apoptosis by promoting ADORA2A in lipopolysaccharide-induced acute lung injury.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36456564","citation_count":13,"is_preprint":false},{"pmid":"32473369","id":"PMC_32473369","title":"Taoren-dahuang herb pair reduces eicosanoid metabolite shifts by regulating ADORA2A degradation activity in ischaemia/reperfusion injury rats.","date":"2020","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32473369","citation_count":13,"is_preprint":false},{"pmid":"28215251","id":"PMC_28215251","title":"The association between caffeine consumption and objective sleep variables is dependent on ADORA2A c.1083T>C genotypes.","date":"2016","source":"Sleep medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28215251","citation_count":12,"is_preprint":false},{"pmid":"33275249","id":"PMC_33275249","title":"Serum expression of EAAT2 and ADORA2A in patients with different degrees of Alzheimer's disease.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33275249","citation_count":11,"is_preprint":false},{"pmid":"36430879","id":"PMC_36430879","title":"Analysis of ADORA2A rs5760423 and CYP1A2 rs762551 Genetic Variants in Patients with Alzheimer's Disease.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430879","citation_count":11,"is_preprint":false},{"pmid":"38494098","id":"PMC_38494098","title":"Adora2A downregulation promotes caffeine neuroprotective effect against LPS-induced neuroinflammation in the hippocampus.","date":"2024","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/38494098","citation_count":9,"is_preprint":false},{"pmid":"39373701","id":"PMC_39373701","title":"Brain Specific RagA Overexpression Triggers Depressive-Like Behaviors in Mice via Activating ADORA2A Signaling Pathway.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39373701","citation_count":8,"is_preprint":false},{"pmid":"35034552","id":"PMC_35034552","title":"Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35034552","citation_count":8,"is_preprint":false},{"pmid":"38931158","id":"PMC_38931158","title":"Effect of ADORA2A Gene Polymorphism and Acute Caffeine Supplementation on Hormonal Response to Resistance Exercise: A Double-Blind, Crossover, Placebo-Controlled Study.","date":"2024","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/38931158","citation_count":7,"is_preprint":false},{"pmid":"32182774","id":"PMC_32182774","title":"The SNP rs2298383 Reduces ADORA2A Gene Transcription and Positively Associates with Cytokine Production by Peripheral Blood Mononuclear Cells in Patients with Multiple Chemical Sensitivity.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32182774","citation_count":7,"is_preprint":false},{"pmid":"37049474","id":"PMC_37049474","title":"The ADORA2A TT Genotype Is Associated with Anti-Inflammatory Effects of Caffeine in Response to Resistance Exercise and Habitual Coffee Intake.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/37049474","citation_count":7,"is_preprint":false},{"pmid":"32969158","id":"PMC_32969158","title":"The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study.","date":"2020","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32969158","citation_count":7,"is_preprint":false},{"pmid":"39976204","id":"PMC_39976204","title":"Adenosine Monophosphate Improves Lipolysis in Obese Mice by Reducing DNA Methylation via ADORA2A Activation by Ecto-5'-Nucleotidase (CD73).","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39976204","citation_count":7,"is_preprint":false},{"pmid":"32448869","id":"PMC_32448869","title":"Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis.","date":"2020","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/32448869","citation_count":7,"is_preprint":false},{"pmid":"34685481","id":"PMC_34685481","title":"Genetics and Cognitive Vulnerability to Sleep Deprivation in Healthy Subjects: Interaction of ADORA2A, TNF-α and COMT Polymorphisms.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34685481","citation_count":6,"is_preprint":false},{"pmid":"37401656","id":"PMC_37401656","title":"Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.","date":"2023","source":"Advanced biology","url":"https://pubmed.ncbi.nlm.nih.gov/37401656","citation_count":6,"is_preprint":false},{"pmid":"27846189","id":"PMC_27846189","title":"The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate.","date":"2017","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27846189","citation_count":6,"is_preprint":false},{"pmid":"31140226","id":"PMC_31140226","title":"ADORA2A Polymorphisms Influence Methotrexate Adverse Events in Rheumatoid Arthritis.","date":"2019","source":"The Israel Medical Association journal : IMAJ","url":"https://pubmed.ncbi.nlm.nih.gov/31140226","citation_count":5,"is_preprint":false},{"pmid":"32432317","id":"PMC_32432317","title":"Methylation-mediated down-regulation of microRNA-497-195 cluster confers osteogenic differentiation in ossification of the posterior longitudinal ligament of the spine via ADORA2A.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32432317","citation_count":5,"is_preprint":false},{"pmid":"37063258","id":"PMC_37063258","title":"Association of the ADORA2A receptor and CD73 polymorphisms with epilepsy.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37063258","citation_count":4,"is_preprint":false},{"pmid":"36833216","id":"PMC_36833216","title":"Sleep Quality and Duration in Children That Consume Caffeine: Impact of Dose and Genetic Variation in ADORA2A and CYP1A.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36833216","citation_count":4,"is_preprint":false},{"pmid":"38892324","id":"PMC_38892324","title":"Genetic Polymorphisms of P2RX7 but Not of ADORA2A Are Associated with the Severity of SARS-CoV-2 Infection.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38892324","citation_count":4,"is_preprint":false},{"pmid":"37560748","id":"PMC_37560748","title":"Adenosine A2A receptor gene polymorphisms (ADORA2A) are associated with maximal concentric contraction pain.","date":"2018","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/37560748","citation_count":3,"is_preprint":false},{"pmid":"36932924","id":"PMC_36932924","title":"Genistein attenuates renal ischemia-reperfusion injury via ADORA2A pathway.","date":"2023","source":"Human & experimental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36932924","citation_count":3,"is_preprint":false},{"pmid":"38764528","id":"PMC_38764528","title":"Peripheral Expression of ADORA2A Is Increased and Is Correlated with Autism Spectrum Disorder Severity in a Sample of Turkish Children.","date":"2023","source":"Psychiatry and clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38764528","citation_count":3,"is_preprint":false},{"pmid":"39548191","id":"PMC_39548191","title":"New MiniPromoter Ple389 (ADORA2A) drives selective expression in medium spiny neurons in mice and non-human primates.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39548191","citation_count":3,"is_preprint":false},{"pmid":"35724635","id":"PMC_35724635","title":"7-Methylxanthine Influences the Behavior of ADORA2A-DRD2 Heterodimers in Human Retinal Pigment Epithelial Cells.","date":"2022","source":"Ophthalmic research","url":"https://pubmed.ncbi.nlm.nih.gov/35724635","citation_count":3,"is_preprint":false},{"pmid":"38731962","id":"PMC_38731962","title":"Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38731962","citation_count":2,"is_preprint":false},{"pmid":"35532631","id":"PMC_35532631","title":"The Influence of ADORA2A on Levodopa-Induced Dyskinesia.","date":"2022","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/35532631","citation_count":1,"is_preprint":false},{"pmid":"38545853","id":"PMC_38545853","title":"Epigenetics and suicide: investigating altered H3K14ac unveiled differential expression in ADORA2A, B4GALT2 and MMP14.","date":"2024","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/38545853","citation_count":1,"is_preprint":false},{"pmid":"36014860","id":"PMC_36014860","title":"Can the Brazilian Caffeine Expectancy Questionnaires Differentiate the CYP1A2 and ADORA2A Gene Polymorphisms?-An Exploratory Study with Brazilian Athletes.","date":"2022","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36014860","citation_count":1,"is_preprint":false},{"pmid":"41261949","id":"PMC_41261949","title":"Caffeine exacerbates exercise-induced gut cell damage and is influenced by ADORA2A genotype but not CYP1A2 genotype: A preliminary study.","date":"2025","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/41261949","citation_count":1,"is_preprint":false},{"pmid":"33342966","id":"PMC_33342966","title":"Impact of the Polymorphism rs5751876 of the Purinergic Receptor ADORA2A on Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention.","date":"2020","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/33342966","citation_count":1,"is_preprint":false},{"pmid":"40751907","id":"PMC_40751907","title":"Association study of ADORA2A gene polymorphisms with adverse drug reactions to valproic acid and oxcarbazepine in the treatment of children with epilepsy.","date":"2025","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/40751907","citation_count":0,"is_preprint":false},{"pmid":"41533917","id":"PMC_41533917","title":"Inhibition of Retinal AdoRA2a Activity Attenuates Myopia Progression.","date":"2026","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/41533917","citation_count":0,"is_preprint":false},{"pmid":"40932634","id":"PMC_40932634","title":"Precision Targeting in Gastric Cancer: AI-Driven Discovery of MET, ADORA2A, CDK5R1, and ADORA1.","date":"2025","source":"Assay and drug development technologies","url":"https://pubmed.ncbi.nlm.nih.gov/40932634","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.29.679179","title":"Associative memory in human cancer cells","date":"2025-09-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.29.679179","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.15.659794","title":"Generation of knock-in Cre and FlpO mouse lines for precise targeting of striatal projection neurons and dopaminergic neurons","date":"2025-06-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.15.659794","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.03.611039","title":"Prenatal exposure to valproic acid induces sex-specific alterations in cortical and hippocampal neuronal structure and function in rats","date":"2024-09-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.03.611039","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.08.601789","title":"Elucidating Interactome Dynamics of the A2A Adenosine Receptor","date":"2024-07-11","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.08.601789","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43020,"output_tokens":5155,"usd":0.103193,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13410,"output_tokens":3774,"usd":0.0807,"stage2_stop_reason":"end_turn"},"total_usd":0.183893,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"RDC8 (ADORA2A) encodes an adenosine A2 receptor that, when expressed in Y1 adrenal cells, dog thyrocytes, and Xenopus oocytes, constitutively activates adenylyl cyclase and the cAMP cascade; this activity was inhibited by adenosine deaminase and adenosine A2 receptor inhibitors. COS7 cells transfected with RDC8 cDNA acquired adenosine A2 receptor binding characteristics.\",\n      \"method\": \"Heterologous expression in multiple cell systems (Y1 adrenal cells, primary thyrocytes, Xenopus oocytes, COS7 cells); adenylyl cyclase activity assay; radioligand binding assay; pharmacological inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted receptor activity in multiple heterologous systems with pharmacological validation and binding assays; replicated across three cell systems in single study\",\n      \"pmids\": [\"2125216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"ADORA2A (RDC8) mRNA is expressed exclusively by enkephalin-containing medium spiny neurons in the rat striatum, and not by substance P-containing or cholinergic neurons, as determined by in situ hybridization histochemistry.\",\n      \"method\": \"In situ hybridization histochemistry combined with neurochemical phenotyping in rat caudate-putamen\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in situ hybridization with cell-type co-localization, single lab but two orthogonal marker systems tested\",\n      \"pmids\": [\"1713612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human ADORA2A gene consists of two exons interrupted by an intron of ~6.4 kb, and the gene is localized to chromosome 22q11.2 by fluorescent in situ hybridization and PCR analysis of human-hamster hybrid cell panels.\",\n      \"method\": \"Genomic cloning, sequence analysis, fluorescent in situ hybridization (FISH), PCR of human-hamster hybrid cell panels\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct chromosomal mapping with two orthogonal methods (FISH and somatic cell hybrid PCR), single lab\",\n      \"pmids\": [\"8670304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADORA2A diplotype AA (homozygous haplotype A) is associated with higher ADORA2A mRNA and protein expression in both brain samples and lymphoblasts, and with higher cAMP production in lymphoblasts in response to adenosine, compared to BB diplotype, demonstrating that genetic variation functionally alters ADORA2A-mediated cAMP signaling.\",\n      \"method\": \"mRNA expression quantification in brain and lymphoblasts; Western blot for protein; cAMP assay in lymphoblasts stratified by diplotype\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal functional readouts (mRNA, protein, cAMP) in two tissue types, single lab\",\n      \"pmids\": [\"23535492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Inducible endothelial cell-specific deletion of Adora2a in mice protects against blood-brain barrier (BBB) breakdown, vascular inflammation, deficits in hippocampal synaptic plasticity, and cognitive impairment induced by high-fat diet/insulin resistance, establishing that Adora2a-mediated signaling in vascular endothelial cells directly mediates BBB disruption.\",\n      \"method\": \"Inducible conditional knockout (endothelial-specific Adora2a deletion); BBB permeability assays (sodium fluorescein, Evans blue); transmission electron microscopy of tight junctions; behavioral memory tests; electrophysiology (synaptic plasticity)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic ablation with multiple orthogonal phenotypic readouts (permeability, EM ultrastructure, cognition, LTP), plus pharmacological validation\",\n      \"pmids\": [\"30886019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SNP rs2298383 in ADORA2A reduces ADORA2A mRNA transcript levels in peripheral blood mononuclear cells (PBMCs); the TT mutated genotype (lower ADORA2A expression) is associated with higher IFNG mRNA levels, suggesting that reduced A2AR signaling promotes a pro-inflammatory phenotype.\",\n      \"method\": \"RT-qPCR quantification of ADORA2A, IFNG, and IL4 mRNA in PBMCs stratified by rs2298383 genotype; correlation analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct mRNA quantification showing genotype-dependent expression differences with functional immune correlate, single lab, two transcriptional readouts\",\n      \"pmids\": [\"32182774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Adenosine activates ADORA2A to promote phosphorylation of Stat3 and Akt, resulting in increased Ang (angiogenin)-dependent angiogenesis in placental endothelial cells; ADORA2A overexpression or adenosine treatment reverses impaired angiogenesis in IUGR placenta in vitro and in vivo.\",\n      \"method\": \"In vitro angiogenesis assays; Matrigel plug assay in vivo; Western blot for phospho-Stat3 and phospho-Akt; ADORA2A overexpression and pharmacological manipulation in diet-induced IUGR mouse model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo gain-of-function with defined downstream signaling (pStat3/pAkt) and functional angiogenesis readout, single lab\",\n      \"pmids\": [\"37051927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADORA2A activation rewires proline metabolism via an ERK/MYC/PYCR cascade; increased proline synthesis promotes SIRT6/7-mediated deacetylation of H3K27, driving a neuroendocrine transcriptional program. Genetic ablation of Adora2a in mouse models inhibits neuroendocrine prostate and lung cancer development and prevents adenocarcinoma-to-neuroendocrine phenotypic transition.\",\n      \"method\": \"Genetically engineered mouse models (Adora2a ablation); RNA-seq; ChIP for H3K27ac/H3K27me3; metabolomics (proline); Western blot for ERK/MYC/PYCR/SIRT6/7; pharmacological ADORA2A blockade in vivo; in vitro signaling assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (metabolomics, epigenomics, transcriptomics, genetic KO, pharmacology) in both mouse models and cell lines defining a complete mechanistic pathway\",\n      \"pmids\": [\"38099497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"JMJD3-mediated H3K27me3 demethylation upregulates ADORA2A expression in macrophages (with C/EBPβ as an additional transcriptional enhancer of ADORA2A), and elevated ADORA2A inhibits caspase-3 cleavage to suppress macrophage apoptosis during LPS-induced acute lung injury.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for H3K27me3 at ADORA2A locus; JMJD3 inhibition/overexpression; ADORA2A knockdown; flow cytometry for apoptosis; TUNEL staining; Western blot for cleaved caspase-3; in vivo ALI mouse model\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates epigenetic regulation of ADORA2A, knockdown with apoptosis readout, in vitro and in vivo, single lab\",\n      \"pmids\": [\"36456564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADORA2A is upregulated by ADORA2A methylation via miR-497/miR-195 downregulation in ossification of the posterior longitudinal ligament (OPLL); miR-195 and miR-497 directly target ADORA2A 3'UTR, and overexpression of these miRNAs inactivates the cAMP/PKA signaling pathway via ADORA2A downregulation to reduce osteogenic differentiation of PLL cells.\",\n      \"method\": \"Luciferase reporter assay (miRNA target validation); qRT-PCR and Western blot for ADORA2A, osteogenic markers; cAMP/PKA pathway analysis; bisulfite sequencing for promoter methylation; demethylation with 5-aza-2'-deoxycytidine\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — validated miRNA-ADORA2A interaction and downstream cAMP/PKA signaling with multiple methods, single lab\",\n      \"pmids\": [\"32432317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADORA2A knockdown in colorectal carcinoma cell lines (SW620, HCT116) inhibits cell proliferation, migration, and invasion, reduces anti-apoptotic Bcl-2 expression, and increases Bax/cleaved caspase-3/cleaved caspase-9, while ADORA2A overexpression has the opposite effect; these effects are mediated through the PI3K/AKT signaling pathway.\",\n      \"method\": \"siRNA knockdown; plasmid overexpression; CCK-8, colony formation, wound healing, transwell assays; flow cytometry for apoptosis; Western blot for PI3K/AKT pathway proteins and apoptosis markers\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function with multiple cellular readouts and defined pathway involvement, single lab\",\n      \"pmids\": [\"37945707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PARP1-mediated PARylation of POLG leads to PARylation-dependent ubiquitination and downregulation of POLG, causing mitochondrial dysfunction and subsequent activation of Adora2a/Rap1 signaling, which drives vascular smooth muscle cell ferroptosis and vascular calcification.\",\n      \"method\": \"VSMC β-glycerophosphate calcification model; PARP1 knockdown (Parp1flox/flox Tagln-Cre+ mice); AAV9-sh-POLG injection; RNA-sequencing; Western blot for PARylation, ubiquitination, Adora2a, Rap1; mitochondrial function assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic in vivo model with RNA-seq pathway identification and Western blot validation, single lab, downstream signaling defined\",\n      \"pmids\": [\"40401372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AMP is converted to adenosine by ecto-5'-nucleotidase (CD73), and the resulting adenosine activates ADORA2A signaling to reduce DNA methylation of hormone-sensitive lipase (HSL) promoter, promoting HSL transcription and white fat lipolysis. This effect is partially eliminated in ADORA2A knockout mice and restored by ADORA2A re-expression.\",\n      \"method\": \"ADORA2A knockout mice; ADORA2A re-expression; bisulfite sequencing for HSL methylation; qRT-PCR for HSL transcription; CD73 inhibition; metabolic phenotyping on high-fat diet\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with rescue and defined epigenetic mechanism (HSL methylation), multiple methods, single lab\",\n      \"pmids\": [\"39976204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADORA2A and DRD2 form heterodimers that co-localize in human retinal pigment epithelial (RPE) cells, as demonstrated by immunofluorescence and co-immunoprecipitation. Treatment with the ADORA2A antagonist 7-methylxanthine reduces ADORA2A expression and increases DRD2, ERK1/2, and phospho-ERK1/2 expression, indicating that ADORA2A inhibits the DRD2/ERK signaling pathway in these cells.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence co-localization; siRNA knockdown of ADORA2A or DRD2; Western blot for ERK1/2, pERK1/2, DRD2; pharmacological treatment with 7-MX\",\n      \"journal\": \"Ophthalmic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and co-localization with functional downstream signaling validation, single lab\",\n      \"pmids\": [\"35724635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Retina-specific AdoRA2a knockout (AdoRA2a-CKO) mice and pharmacological AdoRA2a antagonism with KW6002 both attenuate form-deprivation myopia progression in mice. AdoRA2a co-localizes with dopamine D2 receptor (Drd2) in the retina, and KW6002 has no inhibitory effect on myopia in Drd2-CKO mice, establishing that retinal AdoRA2a acts upstream of Drd2 to regulate myopia.\",\n      \"method\": \"Retina-specific conditional knockout (AdoRA2a-CKO); Drd2-CKO epistasis experiment; pharmacological antagonism (KW6002); refraction measurement; immunofluorescence co-localization; measurement of retinal adenosine and CD39/CD73\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double KO experiment) with conditional KO and pharmacological confirmation, multiple orthogonal approaches defining AdoRA2a-Drd2 pathway\",\n      \"pmids\": [\"41533917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Brain-specific RagA overexpression in transgenic mice upregulates ADORA2A expression in prefrontal cortex (confirmed by Western blot and RNA-seq), and the ADORA2A inhibitor istradefylline attenuates depressive-like behaviors in these mice, placing ADORA2A downstream of the RagA-p70S6K signaling pathway in depression-related behavior.\",\n      \"method\": \"RagA transgenic mice; RNA-seq of prefrontal cortex; Western blot for ADORA2A and phospho-p70S6K; behavioral assessments (depression-like tests); pharmacological ADORA2A inhibition with istradefylline; metabolomics\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic overexpression with RNA-seq identification and pharmacological rescue, single lab, defined pathway position\",\n      \"pmids\": [\"39373701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Using a MiniPromoter derived from ADORA2A regulatory regions (Ple389), selective expression was achieved in medium spiny neurons of the striatum in mice and non-human primates, with high co-localization with dopamine D2 receptor-expressing MSNs and DARPP32, directly establishing that ADORA2A regulatory elements drive expression in D2-MSNs.\",\n      \"method\": \"rAAV-PHP.B delivery of MiniPromoter-reporter constructs; intravenous and intracerebroventricular injection in mice and NHP; immunofluorescence co-localization with D2R and DARPP32; histological analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo localization experiments in two species with orthogonal marker co-localization, single lab\",\n      \"pmids\": [\"39548191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Genistein activates ADORA2A in renal tubular cells (NRK-52E); ADORA2A overexpression mimics genistein's protective effects against hypoxia/reoxygenation-induced oxidative stress and apoptosis, while ADORA2A knockdown partially abrogates genistein's protection, establishing ADORA2A as the functional mediator of genistein's renoprotective effects.\",\n      \"method\": \"ADORA2A overexpression and siRNA knockdown in NRK-52E cells; H/R injury model; in vivo renal IR mouse model; cell proliferation, apoptosis, and oxidative stress assays\",\n      \"journal\": \"Human & experimental toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with in vitro and in vivo correlation, single lab\",\n      \"pmids\": [\"36932924\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADORA2A encodes a G protein-coupled adenosine A2A receptor that constitutively activates adenylyl cyclase/cAMP signaling upon adenosine binding; it is selectively expressed in striatal D2-type medium spiny neurons (enkephalinergic subpopulation), and in endothelial, immune, and other cell types where it mediates diverse downstream cascades including ERK/MYC/PYCR-driven proline synthesis and H3K27 deacetylation (promoting neuroendocrine lineage plasticity), PI3K/AKT (promoting cancer cell survival), Stat3/Akt (promoting angiogenesis), cAMP/PKA (regulating osteogenesis), and Adora2a/Rap1 (promoting VSMC ferroptosis), as well as heterodimerizing with DRD2 to modulate ERK signaling; in the brain its signaling mediates caffeine-sensitive sleep regulation, vigilance, and BBB integrity, and its expression is itself regulated epigenetically by H3K27me3 demethylation (via JMJD3) and by miR-195/miR-497-dependent promoter methylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADORA2A encodes a G protein-coupled adenosine A2A receptor that, upon adenosine binding, activates adenylyl cyclase and the cAMP cascade — an activity reconstituted in multiple heterologous expression systems and blocked by adenosine deaminase and A2 receptor antagonists [#0]. In the brain it is expressed selectively by enkephalin-containing, D2-type medium spiny neurons of the striatum, and its regulatory elements are sufficient to drive D2-MSN-specific expression in mice and non-human primates [#1, #16]. Through cAMP/PKA the receptor signals in diverse peripheral tissues: it drives osteogenic differentiation [#9], promotes white adipose lipolysis by reducing methylation of the HSL promoter [#12], and supports endothelial functions including Stat3/Akt-dependent angiogenesis [#6] and, when active in vascular endothelium, blood-brain barrier breakdown and associated cognitive impairment [#4]. In cancer contexts ADORA2A promotes survival and progression: it sustains colorectal carcinoma proliferation and invasion via PI3K/AKT [#10], and rewires proline metabolism through an ERK/MYC/PYCR cascade that fuels SIRT6/7-mediated H3K27 deacetylation to drive a neuroendocrine transcriptional program in prostate and lung cancer [#7]. The receptor also forms heterodimers with the dopamine D2 receptor (DRD2), acting upstream of DRD2/ERK signaling in retinal cells to modulate processes including myopia progression [#13, #14]. ADORA2A expression is itself epigenetically controlled — induced by JMJD3-mediated H3K27me3 demethylation in macrophages [#8] and repressed by miR-195/miR-497 and promoter methylation [#9] — and common diplotype variation functionally tunes its mRNA, protein, and cAMP output [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established that the orphan clone RDC8 encodes a functional adenosine A2 receptor coupled to cAMP, defining the receptor's core biochemical activity.\",\n      \"evidence\": \"Heterologous expression in Y1 adrenal cells, thyrocytes, Xenopus oocytes and COS7 cells with adenylyl cyclase and radioligand binding assays plus pharmacological inhibition\",\n      \"pmids\": [\"2125216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural basis for adenosine binding or G protein coupling defined\", \"Did not address endogenous tissue distribution or physiological role\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Localized receptor expression to a defined neuronal population, linking ADORA2A to striatal circuitry by showing it marks enkephalinergic medium spiny neurons.\",\n      \"evidence\": \"In situ hybridization with neurochemical phenotyping in rat caudate-putamen\",\n      \"pmids\": [\"1713612\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Descriptive expression mapping without functional consequence\", \"Rodent striatum only\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved the human gene architecture and chromosomal position, providing the genomic substrate for later variant and regulatory studies.\",\n      \"evidence\": \"Genomic cloning, FISH, and PCR of human-hamster hybrid panels\",\n      \"pmids\": [\"8670304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No regulatory element or promoter function assigned\", \"No link to phenotype\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated that common ADORA2A haplotype variation functionally alters signaling output, connecting genotype to expression and cAMP response.\",\n      \"evidence\": \"Diplotype-stratified mRNA, Western blot, and cAMP assays in human brain and lymphoblasts\",\n      \"pmids\": [\"23535492\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative across genotype groups, no causal allelic substitution\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that endothelial ADORA2A signaling causally drives blood-brain barrier breakdown and cognitive impairment, defining a vascular role distinct from its neuronal one.\",\n      \"evidence\": \"Endothelial-specific inducible Adora2a knockout with BBB permeability, EM, behavior and LTP readouts plus pharmacology\",\n      \"pmids\": [\"30886019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effector pathway in endothelium not resolved\", \"Mouse model only\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected ADORA2A to angiogenesis and immune tone, identifying Stat3/Akt-dependent angiogenesis and a genotype-linked pro-inflammatory phenotype with reduced receptor expression.\",\n      \"evidence\": \"Placental endothelial angiogenesis and Matrigel assays with pStat3/pAkt readouts (37051927); rs2298383-stratified PBMC RT-qPCR of ADORA2A/IFNG (32182774)\",\n      \"pmids\": [\"37051927\", \"32182774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Immune correlation is associative, no mechanistic link to IFNG transcription\", \"Two distinct tissue contexts not integrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established ADORA2A as a node controlled by miRNA and promoter methylation that drives osteogenic differentiation through cAMP/PKA.\",\n      \"evidence\": \"Luciferase 3'UTR target validation, bisulfite sequencing, demethylation, and cAMP/PKA analysis in OPLL PLL cells\",\n      \"pmids\": [\"32432317\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Disease specificity to OPLL not generalized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined epigenetic and dimerization-based control of the receptor: JMJD3/H3K27me3 induces ADORA2A to suppress macrophage apoptosis, and ADORA2A heterodimerizes with DRD2 to inhibit DRD2/ERK signaling.\",\n      \"evidence\": \"ChIP at ADORA2A locus with apoptosis assays in ALI model (36456564); co-IP, co-localization and ERK readouts in RPE cells (35724635)\",\n      \"pmids\": [\"36456564\", \"35724635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Anti-apoptotic mechanism downstream of receptor not detailed\", \"Heterodimer interface and stoichiometry undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed two pro-survival/pro-progression cancer axes: an ERK/MYC/PYCR-proline-SIRT6/7-H3K27 deacetylation cascade driving neuroendocrine plasticity, and PI3K/AKT-driven proliferation in colorectal carcinoma.\",\n      \"evidence\": \"GEMM Adora2a ablation with metabolomics, ChIP, RNA-seq and pharmacology (38099497); reciprocal knockdown/overexpression with PI3K/AKT and apoptosis readouts in colorectal lines (37945707)\",\n      \"pmids\": [\"38099497\", \"37945707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How adenosine signaling selectively engages ERK/MYC vs PI3K/AKT in different tumors unclear\", \"Renoprotective genistein-ADORA2A axis (36932924) characterized only correlatively\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Used genetic epistasis to place retinal ADORA2A upstream of DRD2 in controlling myopia, and positioned ADORA2A downstream of RagA-p70S6K signaling in depression-related behavior.\",\n      \"evidence\": \"Retina-specific and Drd2 double-KO epistasis with KW6002 pharmacology (41533917); RagA transgenic mice with RNA-seq and istradefylline rescue (39373701); MiniPromoter D2-MSN expression mapping (39548191)\",\n      \"pmids\": [\"41533917\", \"39373701\", \"39548191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of ADORA2A-DRD2 functional epistasis in retina not resolved\", \"Connection between RagA pathway and ADORA2A transcription not mechanistically defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended ADORA2A signaling to metabolic and vascular pathology, linking CD73-derived adenosine to HSL-driven lipolysis and PARP1/POLG-driven mitochondrial dysfunction to Adora2a/Rap1-mediated VSMC ferroptosis.\",\n      \"evidence\": \"ADORA2A KO with rescue and HSL bisulfite sequencing in adipose (39976204); VSMC calcification model with PARP1/POLG genetic manipulation and RNA-seq (40401372)\",\n      \"pmids\": [\"39976204\", \"40401372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which receptor signaling alters HSL promoter methylation not defined\", \"Adora2a/Rap1-ferroptosis link is correlative within the calcification model\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single cAMP-coupled receptor selects among its many downstream effector outcomes (cAMP/PKA, Stat3/Akt, PI3K/AKT, ERK/MYC, Rap1) across cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking ligand/cell context to effector choice\", \"No structural data on G protein coupling or DRD2 heterodimer in the corpus\", \"Most downstream cascades shown in single cell systems\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 6, 10]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DRD2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}